<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) continues to rise in prevalence in the United States and worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Despite advances in medical treatments for T2DM, many patients remain uncontrolled </plain></SENT>
<SENT sid="2" pm="."><plain>By targeting centrally mediated pathways of <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> represents a novel therapeutic option in T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>Several small clinical trials demonstrate improvements in <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and glycemic control </plain></SENT>
<SENT sid="4" pm="."><plain>After the submission of data from four recent, large clinical trials, the US Food and Drug Administration has approved the use of <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> in T2DM </plain></SENT>
<SENT sid="5" pm="."><plain>We review the available data from these four trials and other published studies </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="3181">Bromocriptine</z:chebi> is a promising therapy for <z:mp ids='MP_0002055'>diabetes</z:mp> patients and demonstrates modest improvements in glycemic control </plain></SENT>
</text></document>